194 related articles for article (PubMed ID: 37999133)
21. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
[TBL] [Abstract][Full Text] [Related]
22. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
Crook J; Rodgers JP; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Murtha AD; Vigneault E; Helou J; Michalski JM; Roach M; Beyer D; Jani AB; Horwitz EM; Raben A; Pugh S; Sandler H
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1115-1122. PubMed ID: 34740768
[TBL] [Abstract][Full Text] [Related]
23. Progress in Low Dose Rate Brachytherapy for Prostate Cancer.
McLaughlin PW; Narayana V
Semin Radiat Oncol; 2020 Jan; 30(1):39-48. PubMed ID: 31727298
[TBL] [Abstract][Full Text] [Related]
24. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
25. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
26. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
Urabe F; Miki K; Kimura T; Sasaki H; Tashiro K; Tsutsumi Y; Morikawa M; Minato K; Sato S; Takahashi H; Aoki M; Egawa S
Prostate; 2022 Mar; 82(4):433-441. PubMed ID: 34914134
[TBL] [Abstract][Full Text] [Related]
28. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
29. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
30. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic?
Bittner N; Merrick GS; Butler WM; Galbreath RW; Adamovich E; Wallner KE
Brachytherapy; 2013; 12(1):14-8. PubMed ID: 22884256
[TBL] [Abstract][Full Text] [Related]
31. Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy.
Enei Y; Urabe F; Miki K; Suzuki H; Iwatani K; Tashiro K; Tsuzuki S; Furuta A; Sasaki T; Sato S; Takahashi H; Aoki M; Kimura T
Anticancer Res; 2023 Jul; 43(7):3159-3166. PubMed ID: 37351978
[TBL] [Abstract][Full Text] [Related]
32. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience.
Uribe-Lewis S; Uribe J; Bourke V; Deering C; Higgins D; Mehta S; Mikropoulos C; Otter S; Perna C; Khaksar S; Laing R; Langley S
BJU Int; 2022 Jun; 129(6):723-730. PubMed ID: 34448332
[TBL] [Abstract][Full Text] [Related]
35. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.
Wilcox SW; Aherne NJ; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):125-33. PubMed ID: 25588566
[TBL] [Abstract][Full Text] [Related]
36. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer.
Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y
World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
[TBL] [Abstract][Full Text] [Related]
38. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
[TBL] [Abstract][Full Text] [Related]
39. Dramatically Polarized Opinion on the Role of Brachytherapy Boost in Management of High-risk Prostate Cancer: A Survey of North American Genitourinary Expert Radiation Oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Mitin T
Clin Genitourin Cancer; 2018 Jun; 16(3):e543-e545. PubMed ID: 29452837
[TBL] [Abstract][Full Text] [Related]
40. Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.
D'Angelillo RM; Franco P; De Bari B; Fiorentino A; Arcangeli S; Alongi F
Crit Rev Oncol Hematol; 2015 Feb; 93(2):136-48. PubMed ID: 25459667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
